Purpose: Cyclooxygenase-2 (COX-2) and its metabolite, PGE2 affect multiple tumorigenesis, including angiogenesis, invasion, and tumor-induced immune suppression. Their overexpression is association with impaired immune cell function in many tumors. Indoleamine 2,3-dioxygenase (IDO) is an emerging immuno-regulatory enzyme that can catalyze the initial rate-limiting step in tryptophan catabolism, by causing tryptophan depletion can block T lymphocyte activation, and thus, enable tumor cells to escape from immune system. Although the potential of immunosuppression associated with tumorproduced COX-2 has been suggested, the mechanism of immunosuppression in tumor immunology is not yet well defined. Thus, we hypothesized that the tumor immunity of COX-2 could be partly due to IDO-dependent immune tolerance. To test this hypothesis, we evaluated IDO expression in cancer cells treated with selective COX-2 inhibitor. Materials and Methods: The A549 human adenocarcinoma cell line, murine Lewis lung carcinoma (LLC) cell line and C57Bl/6 mice were used for in vitro and in vivo studies. In vitro studies, A549 cells were treated with various concentrations of COX-2 inhibitor (PTPBS) or PGE2. IDO enzyme activity and protein expression were checked by IDO enzyme activity assay and Western blotting. In vivo study, the 20 mice were randomized into normal control, LLC inoculated control, and low and high selective COX-2 inhibitor (celecoxib 25 or 250 mg/kg/day) treated LLL inoculated mice groups (n=5 per group). At one month, mice were sacrificed and tumor mass was isolated for quantification of IDO expression by immunohistochemical stain and western blotting. Results: In vitro studies, PTPBS treated A549 cells showed a significant decreased in IDO enzyme activity and expression but PGE2 treated A549 cells showed increased in IDO expression. In vivo studies, the tumor mass and lung metastasis were attenuated by celecoxib (respectively, p＜0.05, p＜0.01). Compared with the LLC inoculated control group, mice treated with celecoxib had significant reductions in IDO expression of tumor mass (IDO immunohistochemical stain and western blotting ). Conclusion: The present study reveals that COX-2 inhibitor serves to restore the tumor-induced IDO expression and promotes antitumor reactivity in an immunocompetent murine lung cancer model. These findings further support the suggestion that COX-2 inhibitor is a potential pharmacological immunotherapy in cancer. 
INTRODUCTION
Tumors work out a variety of schemes to create a favorable environment for tumor development and to counteract the effects of host immune effector cells, and these abilities of tumors explain why the immune system often unable to eradicate tumor cells. Recently, cyclooxygenase (COX) has received much attention because of its ability to reduced the anti-tumor capability of the immune system, and to reduce inflammation, carcinogenesis, apoptosis, metastasis and angio-genesis(1∼4). Moreover, because COX-2 can enhance PGE2 production and subsequent cytokine imbalance in vivo, tumor expression of COX-2 may be instrumental in the abrogation of tumor-induced T cell-mediated antitumor responses (3) . Although the potential of immunosuppression associated with tumor-produced COX-2 has been suggested, the mechanism of immunosuppression in tumor immunology is not yet well defined.
According to Sayama et al., cyclooxygenase inhibitors almost completely suppress interferon-mediated IDO induction in mouse lung slices (5) . IDO is an enzyme that catalyzes the initial and rate-limiting step in the catabolism of trytophan along the kynurenine pathway. Thus, by depleting tryptophan locally, IDO appears to block the proliferation of alloreactive T lymphocytes. These cells are extremely sensitive to tryptophan shortages, which cause their arrest in the G1 phase of the cell cycle (6) . IDO over-expression was also observed in cells exposed to interferon-γ, and in certain types of activated macrophages and dendritic cells, thus suggesting a role for IDO in immune response regulation(7∼9).
Because COX-2 expression can reduced tumor immunity, we hypothesized that this effect of COX-2 might be due in part to IDO-induced immune tolerance. To test this hypothesis, we evaluated IDO expression in cancer cells treated with COX-2 inhibitors.
MATERIALS AND METHODS

1) Cell culture
The A549 human adenocarcinoma cell line was obtained from the American Type Culture Collection(Manassas, VA, USA) and were grown in RPMI 1640 medium containing 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 μg/ml), and HEPES (25 mM) at 37 o C in a humidified 5% CO2 water-jacketed incubator. Experiments were performed with A549 cultured in the above-mentioned medium supplemented with 100 uM L-tryptophan. Test compounds of interest were added 30 min before treating cells with IFN-γ (1,000 U/ml or 10,000 U/ml). After culturing for 24 h, cells were lysed and IDO determined.
2) Drugs and chemical compounds
To prepare IFN-γ stimulated A549 cells, cells were incubated with 1,000 U/ml or 10,000 U/ml of IFN-γ (LG Life Science Ltd., Seoul, Korea) in RPMI 1640 medium containing 10% FBS in 5% CO2 at 37 o C.
For in vitro studies, 1-methyl tryptophan (MT, Sigma, MO, USA) was formulated in dimethyl sulfoxide (DMSO) containing 0.1N HCL to improve its solubility. 1μM 1-MT was added into the culture at the same time. The COX-2 inhibitor (PTPBS) was purchased from Sigma-Aldrich (MO, USA). For experiments with COX-2 inhibitor, A549 cells were treated with various concentrations of PTPBS (10 or 50μM) in RPMI 1640 medium containing 10% FBS in 5% CO2 at 37 o C, whereas control cells were treated with DMSO vehicle. At the end of treatment, the cell lysates were prepared for western blot analysis of IDO.
3) IDO activity assay
IDO activity was measured using the method of Takikawa The relative intensity of the IDO band was determined using the SIGMASCAN-PRO program V5.01 (MA, USA). These experiments were performed at least three times using separate sets of cultures.
5) Animal experimental procedure
Eight-week old C57Bl/6 mice were purchased from the 
6) Analysis of microscopic metastasis
Mice bearing tumors were sacrificed on day 28, lungs were removed, rinsed with saline and fixed in 4% paraformaldehyde.
Formalin-fixed whole lungs were sectioned at 2 mm intervals and embedded in paraffin. These embedded tissues were then sectioned at 4μm thick and placed on glass slides, and stained with hematoxylin and eosin (H&E). Lung sections were then analyzed for tumors microscopically under 20× and 100× magnification. Tumor nodules were identified as densely packed large mitotic cells stained strongly with eosin against the normal lung tissue background.
7) Immunohistochemistry
Paraffin-embedded tumor mass sections were prepared on poly-L-lysine-coated slides at 4μm. Sections were dewaxed in xylene and rehydrated in graded alcohol baths. Endogenous 
8) Statistics
All data are expressed as means±standard error of mean (SE). One-way analysis of variance (ANOVA) was used to determine statistically significant differences between groups.
Scheffé's F-test was used to correct for multiple comparisons when statistical significances were identified by ANOVA. A p value of less than 0.05 was considered significant.
RESULTS
1) In vitro studies (1) IDO activity induction is mediated by IFN-γ: In order
to evaluate the effect of IFN-γ on IDO activity, NCI-H292 lung cancer cells were treated with IFN-γ, and IDO activities were determined using IDO immunoassays and enzyme activity assays. IFN-γ induced IDO expression in a dose-dependent manner (Fig. 1A) , and IFN-γ induced IDO enzyme activity was reduced by IDO inhibitor (1-MT) (Fig. 1B) . Fig. 2A) . Western blot analysis of IDO protein in A549 cells after 72 h of COX-2 inhibitor treatment showed that IDO expression was dose-dependently reduced (Fig. 2B) . that LLC tumors grow in C57BL/6 mice due to IDO-induced immune tolerance and that this immune tolerance is attenuated by cyclooxygenase-2. To test this hypothesis, we treated mice with COX-2 inhibitor (celecoxib), to determine this treatment would delay tumor growth. Seven days after LLC cell inoculation, celecoxib was administered by oral gavage for 21 days.
A significant delay in tumor growth was observed in the groups of mice treated with celecoxib as compared with the untreated LLC inoculated control group. However, no significant differences were between groups treated with 25mg/kg and 250 mg/kg of celecoxib (Fig. 3) .
(2) Effect of Celecoxib on LLC inoculated mouse lung microscopic metastasis: Microscopic metastases were observed in the lungs of most mice with a large tumor (Fig. 4) .
Metastatic lung tumors were present on lung surfaces and in lung parenchyma (Fig. 4A ). Quantitative analysis of metastases in LLC cells inoculated control mice and celecoxib treated mice was performed by counting the numbers of H&E stained positive tumors on lung surfaces and within lung parenchyma (Fig. 4B) . Tumor numbers were found to be significantly reduced in celecoxib treated mice versus LLC inoculated untreated controls.
(3) IDO is expressed by mononuclear cells within LLC tumors and COX-2 inhibitors inhibited this IDO expression:
Tumors from LLC bearing mice were immunostained to determine whether IDO is inhibited within tumors by celecoxib.
The cytoplasm of tumor cells from controls stained positively for IDO antibody (Fig. 5) , but tumor masses obtained from celecoxib treated mice, showed lower levels of IDO immunostaining. IDO expression grades for LLC inoculated control mice and celecoxib (25 or 250 mg/kg) treated mice were 2±0, 1±0.7, and 0.6±0.5, respectively (Fig. 5) , and the differences between the LLC control and the celecoxib treated groups were significant (p＜0.05). The celecoxib modestly decreased the expression of COX-2. In addition, there was a corresponding decrease in IDO expression in the tumor lysates by Western blot analysis (Fig. 6 ).
DISCUSSION
The immune system of tumor-bearing hosts fails to respond effectively to tumor antigens. The fact is that although cancers IDO is a rate-limiting enzyme in tryptophan catabolism and is emerging as an important immunoregulatory enzyme (12) .
Conceptually, the suppressive effects of IDO fall into two categories: those mediated by tryptophan depletion, which include its antimicrobial and antiviral effects, and its inhibition of T cell proliferation in some models (6, 13, 14) ; and the effects mediated by the toxic downstream metabolites of tryptophan, which include CD4+ T cell apoptosis and the inhibition of T cell proliferation in other models (15, 16) . By depleting tryptophan from local microenvironments, IDO can block T lymphocyte activation, which are particularly sensitive to the loss of this essential amino acid (17) , and undergo G1 phase of the cell cycle arrest at reduced levels (6) . This role of nutrient (27) . In our studies, the celecoxib doses chosen for the in vivo study were based on the literatures. The low dose (25 mg/kg body weight per day) was based on previously reported work that yielded celecoxib plasma levels of 0.25μg/ml (0.6μmol/L) (28) . The review by Davies and coworkers on celecoxib pharmacokinetics states that adults taking 800 mg daily have plasma levels of 2.8μg/ml (29) . The plasma levels of celecoxib in the low dose group were thus well below those in human subjects on standard celecoxib dosages. In addition, Williams et al. found a serum concentration of 2.3μmol/L in mice consuming 250 mg/kg/day without toxicity (30) . Thus, we chose a high dose of 250 mg/kg to minimize toxicity for the present study. In the relation of celecoxib dosage and metastatic lung nodules, low dose of celecoxib group (25 mg/kg/day) did not reduced the count of metastatic nodules. This finding suggests that more than standard doses are needed.
We conclude that COX-2 inhibition promote tumor immune response by inhibiting IDO activity. Our findings represent a first demonstration of the tumor COX-2 dependent upregulation of IDO, and thus, immune tolerance. Moreover, these effects were found to be reversed when tumor growth was pharmacologically inhibited by COX-2 inhibitors. These findings lend further support to the suggestion that tumor COX-2 maybe an important pharmacologic or genetic therapeutic target in cancer.
